Skip to main content

Advertisement

SpringerLink
Log in

Low-risk prostate cancer and low testosterone: What are the acceptable alternatives?

  • Case Study
  • Published:
Current Urology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. D’Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969–974.

    Article  PubMed  Google Scholar 

  2. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, et al.: Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000, 283:3217–3222.

    Article  PubMed  Google Scholar 

  3. Bill-Axelson A, Holmberg L, Ruutu M, et al.: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977–1984.

    Article  CAS  PubMed  Google Scholar 

  4. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095–2101.

    Article  CAS  PubMed  Google Scholar 

  5. Whitmore WF Jr: Proceedings: the natural history of prostatic cancer. Cancer 1973, 32:1104–1112.

    Article  PubMed  Google Scholar 

  6. Klotz L: Active surveillance for prostate cancer: for whom? J Clin Oncol 2005, 23:8165–8169.

    Article  PubMed  Google Scholar 

  7. Carter HB, Walsh PC, Landis P, Epstein JI: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002, 167:1231–1234.

    Article  PubMed  Google Scholar 

  8. Warlick C, Trock BJ, Lands P, et al.: Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006, 98:355–357.

    Article  PubMed  Google Scholar 

  9. National Comprehensive Cancer Network: Guidelines. Available at http://www.nccn.org. Accessed August 2009.

  10. Walsh PC, DeWeese TL, Eisenberger MA: Clinical practice. Localized prostate cancer. N Engl J Med 2007, 357:2696–2705.

    Article  CAS  PubMed  Google Scholar 

  11. Krahn MD, Bremner KE, Asaria J, et al.: The ten-year rule revisited: accuracy of clinicians’ estimates of life expectancy in patients with localized prostate cancer. Urology 2002, 60:258–263.

    Article  PubMed  Google Scholar 

  12. Litwin MS, Greenfield S, Elkin EP, et al.: Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer 2007, 109:1777–1783.

    Article  PubMed  Google Scholar 

  13. Centers for Disease Control and Prevention: National vital statistics system. Available at http://www.cdc.gov/nchs/nvss.htm. Accessed August 2009.

  14. Isbarn H, Pinthus JH, Marks LS, et al.: Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009 Apr 8 (Epub ahead of print).

  15. Morgentaler A: Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol 2009, 181:972–979.

    Article  PubMed  Google Scholar 

  16. Calof OM, Singh AB, Lee ML, et al.: Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebocontrolled trials. J Gerontol A Biol Sci Med Sci 2005, 60:1451–1457.

    PubMed  Google Scholar 

  17. Chun FK, Haese A, Ahyai SA, et al.: Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008, 113:701–709.

    Article  PubMed  Google Scholar 

  18. Cancer Prognostics and Health Outcomes Unit of the University of Montreal: Available nomograms for prediction of prostate cancer prior to diagnosis. Available at http://www.nomogram.org/full/pros_calc.php. Accessed August 2009.

  19. Chun FK, Suardi N, Capitanio U, et al.: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. Eur Urol 2009, 55:617–628.

    Article  PubMed  Google Scholar 

  20. Abouassaly R, Lane BR, Jones JS: Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Urology 2008, 71:573–577.

    Article  PubMed  Google Scholar 

  21. Walz J, Graefen M, Chun FK, et al.: High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006, 50:498–505.

    Article  PubMed  Google Scholar 

  22. Huggins C, Hodges CV: Studies on prostatic cancer: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293–297.

    CAS  Google Scholar 

  23. Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004, 350:482–492.

    Article  CAS  PubMed  Google Scholar 

  24. Morgentaler A, Rhoden EL: Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006, 68:1263–1267.

    Article  PubMed  Google Scholar 

  25. Hoffman MA, DeWolf WC, Morgentaler A: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000, 163:824–827.

    Article  CAS  PubMed  Google Scholar 

  26. Yamamoto S, Yonese J, Kawakami S, et al.: Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007, 52:696–701.

    Article  CAS  PubMed  Google Scholar 

  27. Ribeiro M, Ruff P, Falkson G: Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer Am J Clin Oncol 1997, 20:605–608.

    Article  CAS  PubMed  Google Scholar 

  28. Kaufman JM, Graydon RJ: Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004, 172:920–922.

    Article  CAS  PubMed  Google Scholar 

  29. Agarwal PK, Oefelein MG: Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005, 173:533–536.

    Article  CAS  PubMed  Google Scholar 

  30. Sarosdy MF: Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007, 109:536–541.

    Article  CAS  PubMed  Google Scholar 

  31. Khera M, Lipshultz LI: The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am 2007, 34:549–553.

    Article  PubMed  Google Scholar 

  32. Morgentaler A: Testosterone therapy for men at risk for or with history of prostate cancer. Curr Treat Options Oncol 2006, 7:363–369.

    Article  PubMed  Google Scholar 

  33. Morgentaler A: Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007, 34:555–563.

    Article  PubMed  Google Scholar 

  34. Rhoden EL, Morgentaler A: Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003, 170:2348–2351.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Miami, Miller School of Medicine, Dominion Towers, 1400 NW 10th Avenue, Suite 506, Miami, FL, 33136, USA

    Mark Soloway

Authors
  1. Mark Soloway
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Soloway.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Soloway, M. Low-risk prostate cancer and low testosterone: What are the acceptable alternatives?. Curr Urol Rep 10, 413–417 (2009). https://doi.org/10.1007/s11934-009-0078-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-009-0078-8

Keywords

Search

Navigation